#China #Shanghai #Senaparib #IMPACT Therapeutics #Pharmanovia

IMPACT Therapeutics Partners with Pharmanovia

In a significant move for cancer treatment accessibility, IMPACT Therapeutics, trading under the ticker symbol 07630.HK, has announced the establishment of an exclusive partnership with Pharmanovia, a leading global pharmaceutical company. This collaboration grants Pharmanovia the exclusive rights to manufacture, develop, and commercialize Senaparib, a potent PARP inhibitor, across Europe, the Middle East and North Africa (MENA), Australia, and New Zealand. This strategic agreement aims to address the critical needs of patients diagnosed with advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Key Highlights of the Exclusive License Agreement

The agreement highlights include:

• - Financial Aspects: IMPACT Therapeutics stands to receive an initial payment followed by milestone payments contingent upon achieving specific commercial objectives, with a total potential compensation reaching €423.5 million. Additionally, IMPACT will gain royalties up to 25% of net product sales.
• - Global Reach: This partnership significantly expands the market access of Senaparib to 66 countries, enhancing its distribution channels and patient access.
• - Regulatory Progress: The European Medicines Agency (EMA) officially accepted the marketing authorization application for Senaparib as a first-line maintenance treatment for advanced ovarian cancer in August 2025, with the approval timeline projected for the latter half of 2026.

Accelerating Patient Access

With this agreement, IMPACT Therapeutics aims not only to strengthen the brand recognition of Senaparib globally but also to accelerate its availability in the licensed territories. By leveraging Pharmanovia's expertise and established market infrastructure, IMPACT hopes to ensure that the treatment reaches those who need it the most soon after receiving the necessary regulatory approvals.

This partnership marks a pivotal step for IMPACT in providing validated therapeutic options to patients outside of China. The seamless synergy between the two companies is expected to enhance their market strategies and operational efficiencies, ultimately providing high-quality therapeutic options for unmet medical needs.

About Senaparib

Senaparib, known as IMP4297, is a novel and highly potent PARP1/2 inhibitor developed in-house by IMPACT Therapeutics. The drug's unique molecular structure ensures excellent selectivity towards its target and provides a wide safety margin. As of January 2025, Senaparib capsules were granted marketing authorization by the Chinese National Medical Products Administration (NMPA) as a first-line maintenance treatment for adult patients with advanced epithelial ovarian cancer, making it a recognized option in the national reimbursement drug list since December 2025. The company continues its robust global clinical and regulatory development efforts for Senaparib, further underscoring its commitment to addressing medical needs worldwide.

Commitment to Innovation

Founded in 2009, IMPACT Therapeutics aims to deliver precise cancer treatments based on synthetic lethality to meet the unmet medical requirements of cancer patients. Following its listing on the Hong Kong Stock Exchange on May 13, 2026, the company is committed to expanding its innovative oncology portfolio, which already includes a comprehensive range of synthetic lethality-based drugs. With strong internal research and development capabilities, IMPACT is one of the limited companies globally to offer commercially available PARP1/2 inhibitors alongside next-generation selective PARP1 inhibitors currently in clinical development.

About Pharmanovia

Pharmanovia is a global specialty pharmaceutical company with a focus on developing innovative specialty drugs and leveraging established brand strengths. The company fuses scientific, medical, regulatory, and commercial expertise to make drugs accessible to patients, reflecting a commitment to improving health outcomes now and in the future. This partnership is expected to create significant synergies and accelerate the delivery of life-changing therapies to patients in today's increasingly complex healthcare landscape.

Through this collaboration, both IMPACT Therapeutics and Pharmanovia are poised to make a tangible impact on global cancer treatment accessibility and innovation.